Moderna, Inc. (NASDAQ:MRNA) Receives $59.00 Consensus Price Target from Brokerages

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-four analysts that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $59.00.

MRNA has been the topic of a number of recent analyst reports. Argus lowered Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Citigroup initiated coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Finally, UBS Group reduced their target price on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th.

Hedge Funds Weigh In On Moderna

Several large investors have recently added to or reduced their stakes in MRNA. Allworth Financial LP raised its holdings in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares during the period. Howard Capital Management Inc. grew its position in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after buying an additional 317 shares during the period. Empowered Funds LLC grew its holdings in shares of Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company's stock valued at $347,000 after acquiring an additional 322 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Moderna Trading Down 0.4 %

Shares of Moderna stock traded down $0.14 on Friday, reaching $34.03. 889,855 shares of the stock were exchanged, compared to its average volume of 6,643,128. The firm has a market capitalization of $13.16 billion, a PE ratio of -3.67 and a beta of 1.86. Moderna has a 1-year low of $29.25 and a 1-year high of $170.47. The business has a fifty day moving average price of $34.89 and a two-hundred day moving average price of $45.39.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.